BioLife Solutions (NASDAQ:BLFS) Director Amy Duross Sells 2,000 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $27.00, for a total transaction of $54,000.00. Following the sale, the director owned 22,687 shares of the company’s stock, valued at approximately $612,549. This represents a 8.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Amy Duross also recently made the following trade(s):

• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The shares were sold at an average price of $26.00, for a total transaction of $26,000.00.
• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The stock was sold at an average price of $24.51, for a total transaction of $110,858.73.
• On Wednesday, November 19th, Amy Duross sold 477 shares of BioLife Solutions stock. The shares were sold at an average price of $24.50, for a total value of $11,686.50.

BioLife Solutions Price Performance

Shares of BLFS opened at $26.54 on Friday. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62. The stock’s 50-day moving average is $26.46 and its two-hundred day moving average is $24.26. The stock has a market cap of $1.28 billion, a PE ratio of -221.15 and a beta of 1.97.

Analyst Ratings Changes

BLFS has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a research note on Monday. Finally, Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.20.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hantz Financial Services Inc. boosted its stake in BioLife Solutions by 54.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 659 shares during the last quarter. State of Wyoming raised its stake in shares of BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,490 shares in the last quarter. Quarry LP lifted its position in shares of BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the last quarter. US Bancorp DE grew its stake in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,528 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its holdings in BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.